Zentalis FY2022 cash $437M, R&D $172.7M; azenosertib RP2D on track for 1H 2023

Zentalis Pharmaceuticals, Inc.

2022-FY EPS reported -$4.48

Cash, cash equivalents and marketable securities of $437.4M as of Dec 31, 2022; projected cash runway into Q2 2025.
R&D expenses $172.7M for FY2022 (vs $175.6M in 2021); G&A expenses $54.5M (vs $40.9M).
On track to declare azenosertib monotherapy RP2D in 1H 2023; Cyclin E1 enrichment strategy in ovarian cancer.
Appointed Iris Roth, PhD as Chief Operating Officer in February 2023.
Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen (Pfizer) in BRAF V600E mCRC.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.